Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide gap-134 administration on experimental atrial fibrillation in dogs

Circulation: Arrhythmia and Electrophysiology

Volumn 2, Issue 2, 2009, Pages 171-178

  Laurent, Gabriel ^a   Leong Poi, Howard ^b,c   Mangat, Iqwal ^b,c   Moe, Gordon W ^b,c   Hu, Xudong ^a,b   So, Petsy Pui Sze ^a,b   Tarulli, Emidio ^c   Ramadeen, Andrew ^a,b   Rossman, Eric I ^d   Hennan, James K ^d   Dorian, Paul ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PFIZER INC   (United States)

Author keywords

Atrial fibrillation; Cardiomyopathy; Gap junctions

Indexed keywords

ANTIARRHYTHMIC PEPTIDE; ANTIARRHYTHMIC PEPTIDE GAP 134; CONNEXIN 43; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CELL COMMUNICATION; CONTROLLED STUDY; DOG; DRUG EFFECT; GAP JUNCTION; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BENZAMIDES; CARDIAC PACING, ARTIFICIAL; CONNEXIN 43; DISEASE MODELS, ANIMAL; DOGS; FIBROSIS; GAP JUNCTIONS; HEART ATRIA; HEART CONDUCTION SYSTEM; IMMUNOHISTOCHEMISTRY; PROLINE; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL;

EID: 69949190470     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.108.790212     Document Type: Article

References (28)

1. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, and Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. V-HeFT Studies. Circulation. 1993; 87:102-110.
2. Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J. Old and new antiarrhythmic drugs for converting and maintaining atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 2003; 91:15D-26D.
3. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002; 415:219 -226.
4. Eloff BC, Gilat E, Wan X, Rosenbaum DS. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy. Circulation. 2003; 108: 3157-3163.
5. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, Kuhn-Regnier F, De Vivie ER, Dhein S. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol. 2001; 38:883- 891.
6. Nattel S, Maguy A, Le Bouter S, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev. 2007; 87:425- 456. (Pubitemid 47084677)
7. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999; 100:87-95.
8. Lampe PD, Lau AF The effects of connexin phosphorylation of gap junctional communication. Int J Biochem Cell Biol. 2004; 36:1171-1186.
9. Spach MS, Starmer CF. Altering the topology of gap junctions; A major therapeutic target for atrial fibrillation. Cardiovas Research. 1990; 30: 336-344.
10. Kjølbye AL, Haugan K, Hennan JK, Petersen JS. Pharmacological modulation of gap junction function with the novel compound Rotigaptide: a promising new principle for prevention of arrhythmias. Basic Clin Pharmacol Toxicol. 2007; 101:215-230.
11. Pogwizd SM. Prevention of ischemia-induced reentrant ventricular arrhythmias by a peptide that enhances gap junctional conductance. J Cardiovasc Electrophysiol. 2003; 14:521-523.
12. Haugan K, Miyamoto T, Takeishi Y, Kubota I, Nakayama J, Shimojo H, Hirose M. Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria. Basic Clin Pharmac Toxic. 2006; 99:71-79.
13. Xing D, Kjolbye AL, Nielsen MS, Pertersen JS, Harlow KW, Holstein- Rathlou NH, Martins JB. ZP123 Increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol. 2003; 14:510 -520.
14. Hennan JK, Swillo RE, Morgan GA, Keith JC Jr, Schaub RG, Smith RP, Feldman HS, Haugan K, Kantrowitz J, Wang PJ, Abu-Qare A, Butera J, Larsen BD, Crandall DL. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduced infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Pharmacol Exp Ther. 2006; 317:236 -243.
15. Zhong JQ, Laurent G, So PP, Hu X, Hennan JK, Dorian P. Effects of Rotigaptide, a gap junction modifier, on defibrillation energy and resuscitation from cardiac arrest in rabbits. J Cardiovac Pharmacol Ther. 2007; 12:69 -77.
16. Guerra JM, Everett TH, Lee KW, Wilson E, Olgin JE. Effects of the gap junction modifier Rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation. 2006; 114:110 -118.
17. Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S. Model-dependent effects of the gap junction conduction- enhancing antiarrhythmic peptide Rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation. 2007; 115:310 -318.
18. Laurent G, Moe GW, Hu X, Pui-Sze So P, Ramadeen A, Leong-Poi H, Doumanovskaia L, Konig A, Trogadis J, Courtman D, Strauss BH, Dorian P. Simultaneous right atrioventricular pacing: a novel model to study atrial remodeling and atrial fibrillation in the setting of heart failure. J Card Fail. 2008; 14:254 -262.
19. Laurent G, Moe G, Hu X, Holub B, Leong-Poi H, Trogadis J, Connelly K, Courtman D, Strauss B, Dorian P. Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model. Cardiovasc Res. 2008; 77:89 -97.
20. Kjolbye AL, Knudsen CB, Jepsen T, Larsen BD, Petersen JS. Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): in vivo and in vitro studies. J Pharmacol Exp Ther. 2003; 306:1191-1199.
21. Everett TH, Wilson EE, Verheule S, Guerra JM, Foreman S, Olgin JE. Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling. Am J Physiol Heart Circ Physiol. 2006; 291:2911-2923.
22. Wijffels MC, Dorland R, Mast F, Alessie MA. Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goats. Effects of cibenzoline, hydroquinidine, flecainide, and D-sotalol. Circulation. 2000; 102:260 -267.
23. Wang J, Bourne GW, Wang Z, Villemaire C, Talajiic M, Nattel S. Comparative mechanism of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use dependant effects on refractoriness. Circulation. 1993; 88:1030 -1044.
24. Qu Z. Critical mass hypothesis revisited: Role of dynamical wave stability in spontaneous termination of cardiac fibrillation. Am J Physiol Heart Circ Physiol. 2006; 290:H255-H263.
25. Stahlhut M, Petersen JS, Hennan JK, Ramirez MT. The antiarrhythmic peptide rotigaptide (ZP123) Increases connexin 43 protein expression in neonatal rat ventricular cardiomyocytes. Cell Commun Adhes. 2006; 13: 21-27.
26. Kjø lbye AL, Dikshteyn M, Eloff BC, Deschênes I, Rosenbaum DS. Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans. Am J Physiol Heart Circ Physiol. 2008; 294:H41-H49.
27. Butera JA, Larsen BD, Hennan JK, Kerns E, Di L, Alimardanov A, Swillo RE, Morgan GA, Liu K, Wang Q, Rossman EI, Unwalla R, McDonald L, Huselton C, Petersen JS. Discovery of (2S, 4R)-1-(2- aminoacetyl)-4-benzamidopyrrolidine-2- carboxylic acid hydrochloride (GAP-134)(13), an orally active small molecule GAP-junction modifier for the treatment of atrial fibrillation. J Med Chem. 2009; Jan 28. [Epub ahead of print].
28. Mantz J, Cordier J, Giaume C. Effects of general anesthetics on intercellular communications mediated by gap junctions between astrocytes in primary culture. Anesthesiology. 1993; 78:892-901.